Bruce N. Jacobs - 12 Jan 2022 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Financial Officer
Signature
/s/ Bruce N. Jacobs
Issuer symbol
KYMR
Transactions as of
12 Jan 2022
Net transactions value
-$746,484
Form type
4
Filing time
14 Jan 2022, 16:01:32 UTC
Previous filing
03 Dec 2021
Next filing
14 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $31,200 +15,000 +86% $2.08* 32,514 12 Jan 2022 Direct
transaction KYMR Common Stock Sale $329,149 -6,427 -20% $51.21 26,087 12 Jan 2022 Direct F1, F2
transaction KYMR Common Stock Sale $372,788 -7,151 -27% $52.13 18,936 12 Jan 2022 Direct F1, F3
transaction KYMR Common Stock Sale $75,747 -1,422 -7.5% $53.27 17,514 12 Jan 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -15,000 -29% $0.000000 36,974 12 Jan 2022 Common Stock 15,000 $2.08 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.70 to $51.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.71 to $52.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.01 to $53.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.